The search and testing of new cancer treatment methods continue, with mRNA technology now being actively trialed within the healthcare system. This new framework is tailored to the specific tumor detected in a patient, meaning the treatment approach is fully personalized. Companies Moderna and Merck are testing their own version in this direction, and their results have already attracted significant attention from specialists. Many believe this method could fundamentally alter general perceptions regarding the future prospects of cancer treatment.
The American pharmaceutical giants have announced successful results from Phase 3 trials of a personalized treatment for melanoma, an aggressive form of skin cancer. The experimental trial involving more than a thousand patients yielded positive outcomes, significantly reducing the risk of melanoma recurrence and spread after surgery. Experts emphasize that this is not a conventional preventive vaccine. It is intended for patients who have already undergone surgery but remain at risk of recurrence. After removing the tumor, doctors thoroughly examine its genetic characteristics, based on which the specific vaccine is created. This method allows targeting up to 34 distinct mutations characteristic of each patient's tumor.
Scientists are now attempting to understand whether the same approach will work for other types of tumors. Moderna and Merck are already studying the application of this technology for treating lung, bladder, and kidney cancers. However, trials do not always end in success. For instance, German company BioNTech was forced to halt its trial for colon cancer treatment due to low efficacy. Furthermore, producing a personalized treatment is quite complex and time-consuming. If further research confirms the method's efficacy, medicine will definitively transition from the "one drug fits all" principle to personalized treatment.
Trials of personalized mRNA vaccines demonstrate that healthcare is entering a new phase in the fight against cancer, where standard protocols will be replaced by treatment tailored at the genetic level. Although the success recorded in the case of melanoma represents major progress, it does not yet mean that a universal solution has been found.
BioNTech's termination of the colon cancer trial serves as a reminder that tumors in each organ possess their own complex biology, and a technology that works for one type may prove ineffective for another. In the next stage, the most critical question will be how quickly and affordably the production of individualized medication can be made available for every patient.
